Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
13D Activist Fund Ken Squire | “This is a U.S. activist campaign by Irenic Capital. Integer is the only publicly traded pure-play medical device CDMO, serving OEMs like Medtronic and Boston Scientific in highly regulated, sticky end markets. A temporary demand air pocket caused shares to fall over 40%, despite management guiding to growth normalization in 2027. Irenic has called for board refreshment and exploration of a potential sale, arguing that Integer is structurally better suited for private ownership. Comparable transactions suggest a valuation north of $120 per share versus roughly 10x EBITDA currently. BSD Analysis: Integer is medtech manufacturing infrastructure embedded deep in customers' supply chains. It doesn't invent devices; it makes sure they actually get built to regulatory standards. Switching suppliers is painful once validation and FDA processes are complete. Investors treat Integer like a generic contract manufacturer and miss the moat created by compliance and quality. Demand tracks procedure volumes and innovation cycles, not consumer sentiment. Margin expansion comes from mix and operational execution. This is picks-and-shovels healthcare with long-cycle stickiness.” | BULL | Q4 2025 Jan 14, 2026 | View Pitch |
Heartland Value Fund The Heartland Investment Team | “An example of a Health Care holding that struggled in the quarter was Integer Holdings Corporation (ITGR), which specializes in the design, development, and production of medical technologies and components. In late October, Integer's stock sank more than 30% after the company significantly lowered its outlook for growth and margin expansion in 2026, as several products experienced slower market adoption than was expected. But management expects these headwinds to be short-lived, with a robust portfolio of higher growth and margin products coming to market, which should allow the company to get back on track. The company still expects to outgrow its industry peers by 2% while growing earnings before interest and taxes (EBIT) at twice the rate of sales. Even better, the company announced a $200 million stock repurchase authorization after the selloff, increasing our conviction that the shares are materially undervalued. This confidence drove us to increase our exposure to Integer in the quarter. BSD Analysis: Integer is a picks-and-shovels medtech supplier—less glamorous than OEMs, but often stickier than investors assume. The moat is qualification and switching friction: regulated components don't get swapped lightly. Growth comes from outsourcing trends and content per procedure, not headline innovation. The failure mode is customer concentration and program ramps that disappoint. Margins depend on manufacturing execution and mix—small errors become big in regulated supply chains. The bull case is steady medtech volume growth with operating leverage. The bear case is pricing pressure from OEMs and utilization shortfalls. Integer is a “quiet compounder” if execution stays clean. If execution slips, it trades like a commodity manufacturer.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Riverwater Partners Small Cap Strategy Nathan Fredrick, CFA | “We sold our position in Integer Holdings Corp. during the quarter. ITGR lowered its revenue and earnings guidance for the fourth quarter and 2026 during its third quarter earnings conference call due to unexpected notification by customers that sales of three new products will decline in 2026, given that market adoption of these products has been slower than forecasted. Given ITGR's limited visibility regarding these products, we chose to sell the position. BSD Analysis: Integer is a contract manufacturer embedded in complex medical device supply chains. Switching suppliers is risky and expensive for OEMs. Demand follows procedure volumes over time. Margins improve with mix shift toward higher-value components. Capacity investments create operating leverage. Investors treat it like generic manufacturing. In reality, qualification barriers matter. As medtech volumes normalize, earnings accelerate. This is hidden medtech leverage.” | BEAR | Q4 2025 Dec 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
